Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Recht

Showing results (121-130 of 135) with videos related to

Pageof 14
Sort By:
European Journal of Haematology|March 21, 2017
Management of US men, women, and children with hemophilia and methods and demographics of the Bridging Hemophilia B Experiences, Results and Opportunities into Solutions (B-HERO-S) studyTyler W Buckner, Michelle Witkop, Christine Guelcher, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|December 16, 2024
Bleed treatment with eptacog beta (rFVIIa) results in a low incidence of rebleeding in adult and adolescent patients with haemophilia A or B with inhibitorsAmy Dunn, Yesim Dargaud, Yasmina Abajas, et al.
Blood Vessels, Thrombosis & Hemostasis|July 1, 2026
Safety and real-world effectiveness of eptacog beta with emicizumab prophylaxis: an interim analysis of the ATHN 16 studyTammuella Chrisentery-Singleton, Suchitra Acharya, Sanjay Ahuja, et al.
Pediatric Blood & Cancer|June 16, 2011
Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopeniaRachael F Grace, Carolyn M Bennett, A Kim Ritchey, et al.
Expert Review of Hematology|March 15, 2023
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for ultra-rare inherited bleeding disordersDiane Nugent, Suchitra S Acharya, Kimberly J Baumann, et al.
The New England Journal of Medicine|November 17, 2021
Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia ALindsey A George, Paul E Monahan, M Elaine Eyster, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 12, 2021
The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitorsMiguel Escobar, Giancarlo Castaman, Santiago Bonanad Boix, et al.
The New England Journal of Medicine|June 11, 2025
Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia BUlrike M Reiss, Andrew M Davidoff, Edward G D Tuddenham, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 27, 2022
Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitorsSteven W Pipe, Cédric Hermans, Meera Chitlur, et al.
The New England Journal of Medicine|August 10, 2007
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophiliaMarilyn J Manco-Johnson, Thomas C Abshire, Amy D Shapiro, et al.
Pageof 14

Showing results (121-130 of 135) with videos related to

Sort By:
Pageof 14
European Journal of Haematology|March 21, 2017
Management of US men, women, and children with hemophilia and methods and demographics of the Bridging Hemophilia B Experiences, Results and Opportunities into Solutions (B-HERO-S) studyTyler W Buckner, Michelle Witkop, Christine Guelcher, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|December 16, 2024
Bleed treatment with eptacog beta (rFVIIa) results in a low incidence of rebleeding in adult and adolescent patients with haemophilia A or B with inhibitorsAmy Dunn, Yesim Dargaud, Yasmina Abajas, et al.
Blood Vessels, Thrombosis & Hemostasis|July 1, 2026
Safety and real-world effectiveness of eptacog beta with emicizumab prophylaxis: an interim analysis of the ATHN 16 studyTammuella Chrisentery-Singleton, Suchitra Acharya, Sanjay Ahuja, et al.
Pediatric Blood & Cancer|June 16, 2011
Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopeniaRachael F Grace, Carolyn M Bennett, A Kim Ritchey, et al.
Expert Review of Hematology|March 15, 2023
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for ultra-rare inherited bleeding disordersDiane Nugent, Suchitra S Acharya, Kimberly J Baumann, et al.
The New England Journal of Medicine|November 17, 2021
Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia ALindsey A George, Paul E Monahan, M Elaine Eyster, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 12, 2021
The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitorsMiguel Escobar, Giancarlo Castaman, Santiago Bonanad Boix, et al.
The New England Journal of Medicine|June 11, 2025
Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia BUlrike M Reiss, Andrew M Davidoff, Edward G D Tuddenham, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 27, 2022
Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitorsSteven W Pipe, Cédric Hermans, Meera Chitlur, et al.
The New England Journal of Medicine|August 10, 2007
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophiliaMarilyn J Manco-Johnson, Thomas C Abshire, Amy D Shapiro, et al.
Pageof 14